Treatment of advanced renal cell carcinoma by recombinant erythropoietin;Traitement du cancer du rein avancé par l'Erythropoïétine recombinante

Progres en Urologie

Volumn 7, Issue 3, 1997, Pages 399-402

  Morere, Jean François ^a   Bouillet, Thierry ^a   Piperno Neumann, Sophie ^a   Tourani, Jean Marc ^b   Brunet, Arlette ^a   Hennebelle, Frédéric ^a   Breau, Jean Luc ^a  

^a AVICENNE HOSPITAL   (France)

^b Hopital Laennec   (France)

Author keywords

Erythropoietin; Renal cancer

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ERYTHROPOIETIN; HEMOGLOBIN; RECOMBINANT PROTEIN;

AGED; ARTICLE; BONE; CANCER STAGING; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; FEMALE; HEADACHE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PAIN; PATHOLOGY; PROSPECTIVE STUDY; REMISSION; SUBCUTANEOUS DRUG ADMINISTRATION; WORLD HEALTH ORGANIZATION;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BONE AND BONES; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; ERYTHROPOIETIN; FEMALE; HEADACHE; HEMOGLOBINS; HUMANS; HYPERTENSION; INJECTIONS, SUBCUTANEOUS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PAIN; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; REMISSION INDUCTION; WORLD HEALTH ORGANIZATION;

EID: 0031158318     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. ABELS R.I. Recombinant human erythropoietin in the treatment of the anaemia of cancer. Acta Haematologica, 1992, 87, suppl. 1, 4-11.
2. BAUER E., DANHAUSER-RIEDL S., DE RIESE W. et al. Effects of recombinant human erythropoietin on clonogenic growth of primary human tumor specimens in vitro. Onkologie, 1992, 15, 254-258.
3. BEAUFILS H., JACQUIAUD C., ADABRA Y. et al. Effect of erythropoietin on cisplatin induced acute renal failure. Proc Am. Soc. Clin. Oncol., 1996, 15, 502.
4. BERDEL W.E., OBERBERG D., RENFI B., THIEL E. Studies on the role of recombinant human erythropoietin in the growth regulation of human non hematopoietic tumor cells in vitro. Ann. Hematol., 1991, 63, 5-8.
5. BORNIG C.C., SQUIRES T.S., TONG T. et al. Cancer statistics. 1994, CA 1994, 44, 7-26.
6. BUZAID A.C., TODD M.B. Therapeutic options in renal cell carcinoma. Seminars Oncology, 1989, 16, 12-19.
7. DE KERNICS J.B., RAMMINGS K.P., SMITH R.B. The natural history of metastatic renal cell carcinoma : a computer analysis. J. Urol., 1983, 130, 2-7.
8. ESCHBACH J.W., EGRIE J.C., DOWNING M.R. et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin : results of the phase I and II clinical trial. N. Engl. J. Med., 1987, 316, 73-78.
9. FRIEDRICH R.E., MESTMACHER P., HELLNER D., ARPOTT. Evidence of a growth inhibition effect of high levels of recombinant human erythropoietin on sarcoma cell lines in vitro. In Kladpor R. (Ed.), Current tumor diagnosis : Applications, clinical relevance, research trends, Zuckschwerdt Verlag, Muenchen, 1994, 780-783.
10. LEITGEB C., PECHERSTORFER M, FRITZ E., LUDWING H. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer, 1994, 73, 2535-2542.
11. MALDARYS J.F., DE KERNICO J.B. Prognostic factors in metastatic renal carcinoma. J. Urol., 1986, 76, 376-377.
12. MEYERS F.S., LI J.H., GUMERLOCK. Interleukin-6 and its receptor in renal cell carcinoma : expression does not predict response to modulation. Proc. Am. Soc. Clin. Oncol., 1995, 13, 123.
13. NEGRIER S., ESCUDIER B., LASSET C. et al. The FNLCC Crecy Trial Interleukin (IL2) + Interferon (IFN) is the optimal treatment to induce responses in metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol., 1996, 15, 248.
14. RUBINS J. Metastatic renal cell carcinoma : response to treatment with human recombinant erythropoietin. Ann. Inter. Med., 1995, 123, 676-677.
15. WESTPHAL G., NIEDERBERGER E., PESCHKE P. et al. Experimental data concerning the safety profile of rh EPO in the treatment of cancer patient. In Smyth J.F., Boogaerts M.A., Ehner B.R.M. (Ed.), r erythropoietin in cancer supportive treatment, Marcel Dekker, Inc., New York, 1996, 149-158.
16. WOLLMAN Y., WESTPHAL G., BLUM M. et al. The effect of human recombinant erythropoietin on the growth of a human neuroblastoma cell lung. Life Sci., 1996, 59, 315-322.
17. WAS E., OLENCKI T., TUCSON L. et al. Phase II trial of subcutaneously administered granulocyte - macrophage colony - stimulating factor in patients with metastatic renal cell carcinoma. Cancer, 1996, 77, 1149-1153.